Online inquiry

IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5904MR)

This product GTTS-WQ5904MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL31RA gene. The antibody can be applied in Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001242636.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 133396
UniProt ID Q8NI17
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5904MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4965MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ9933MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ346MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ42MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ5314MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ5264MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ970MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ9180MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW